Henrik Watz, MD, PhD, presented compelling real-world data at the American Thoracic Society Annual Meeting on the long-term impact of dupilumab therapy in patients with severe asthma.
Participants in the ProVENT study experienced sustained improvements in lung function, asthma control, and quality of life. Notably, more than half achieved asthma remission within two years of treatment.
Cheers to Dr. Watz and our team in Grosshansdorf for supporting this study!
Read more: https://www.hcplive.com/view/dupilumab-treatment-led-to-sustained-asthma-improvements-over-2-years
